Lou Feipeng, a researcher at the Postal Savings Bank: The full implementation of the personal pension system is just the right time for financial institutions to usher in development opportunities. "The full implementation of the personal pension system is just the right time." Lou Feipeng, a researcher at China Postal Savings Bank, said that in the past two years, the personal pension system has achieved remarkable results in general, with a rapid increase in the number of accounts opened and a rapid enrichment of financial products. The data shows that at the end of June 2024, the number of individual pension accounts opened exceeded 60 million. "The implementation of the personal pension system in the pioneering urban areas has enabled the residents to have a more intuitive understanding of the personal pension system. At the same time, it has accumulated rich experience for government departments and financial departments to improve the personal pension system and optimize personal pension financial services. " Yan Feipeng said. (SSE)The Environmental Protection Department of the National Development and Reform Commission organized the liaison meeting of the coordination mechanism of cleaner production promotion departments in 2024. On the afternoon of December 10th, the Environmental Protection Department of the National Development and Reform Commission organized the liaison meeting of the coordination mechanism of cleaner production promotion departments in 2024 to sort out and summarize the latest progress, existing problems and difficulties in the implementation of cleaner production in 2024, study the key tasks in 2025, and promote the completion of the objectives and tasks of the Tenth Five-Year Plan.Mengke Pharmaceutical Co., Ltd.: The new packaging of Contizontamide tablets will be on the market soon. Mengke Pharmaceutical Co., Ltd. announced that the company has launched Contizontamide tablets with new packaging specifications, and a box of 12 tablets will be on the market soon. Contizontamide tablet is a new class 1 oxazolidinone antibacterial drug with global intellectual property rights. It was approved by National Medical Products Administration, China on June 1st, 2021 for the treatment of complex skin and soft tissue infections.
The full implementation of the personal pension system may bring more medium and long-term funds, and the allocation value of the Southern Shanghai and Shenzhen 300ETF(159925) has attracted much attention. On December 12, the Southern Shanghai and Shenzhen 300ETF(159925) closed up 1.07%, with a turnover of 92.5438 million yuan. The constituent stocks were all red, with Contemporary Amperex Technology Co., Limited rising by 2.47%, Kweichow Moutai rising by 1.97% and Wuliangye rising by 1.62%. China Merchants Bank and China Ping An followed suit. In the news, since December 15th, the personal pension system has been extended to the whole country, and the first batch of 85 index funds have been included in the product range, which has attracted attention, including 12 Shanghai and Shenzhen 300 index funds and 300ETF(159925) in South China. According to industry insiders, since the personal pension fund system came into being, both personal pension funds and sales organizations have steadily expanded. The increase of fund products and the continuous addition of new sales organizations will bring more medium and long-term funds to the capital market, and the Southern CSI 300ETF(159925) will benefit in the medium and long term.Zhu Min, former vice president of IMF: Domestic consumption, manufacturing and green transformation will become the growth drivers of China's economy. Recently, at the China 2024 Annual Meeting and the 22nd Financial Billboard, Zhu Min, former vice president of China International Economic Exchange Center, said that one of the three traditional locomotives of China's economic growth is infrastructure investment; The second is the real estate industry, and the third is export. The transformation of the whole economic structure needs a new growth impetus. Zhu Min said that this new growth driver is, first, based on domestic consumption, and second, insisting on doing a good job in domestic manufacturing and doing high technology; The third is green transformation. We will continue to take the road of sustainable development of green transformation in China and improve our core competitiveness.President of Hilton Asia Pacific: India's outbound travel will be the story of the next decade. According to the data of the World Tourism and Travel Council, in 2023, Indian tourists spent $34.2 billion on outbound travel. Allen Watts, president of Hilton Asia Pacific, said that compared with the future, the current level of Indian outbound travel consumption is "negligible". "The story of India is unfolding before us," he said. "India's outbound travel will be the story of the next decade." According to the World Tourism and Travel Council's Economic Impact in 2024 report, by 2034, the outbound spending of Indian tourists is expected to more than double, reaching 76.8 billion US dollars, which will make India's position in the global tourism consumption country rise from the 12th in 2023 to the 7th.
Turkish Defense Ministry source: Syrian allies continue to advance in northern Syria to "eliminate terrorism".Ai Kelan: The actual controller intends to transfer 5% shares of the company by agreement. Ai Kelan announced that Liu Yi, the controlling shareholder and actual controller of the company, intends to transfer 4 million unrestricted shares of the company to Guangdong Nanchuan Private Equity Fund Management Co., Ltd. by agreement transfer, accounting for 5.00% of the company's total share capital. If the transaction is finally completed, Liu Yi holds 33.89% of the company's shares, and Nanchuan Private Equity holds 5.00% of the company's shares. This change in equity will not lead to changes in the controlling shareholder and actual controller of the company. The transfer of shares in this agreement can only be handled in Shenzhen Branch of China Securities Depository and Clearing Co., Ltd. after the compliance confirmation of Shenzhen Stock Exchange. The share transfer price of this transaction is 20.61 yuan/share.The monkeypox vaccine with independent intellectual property rights in China was approved for clinical use. On December 10th, the monkeypox vaccine jointly developed by China Bio-Beijing Institute of Biological Products and China Center for Disease Control and Prevention received the approval notice of drug clinical trial issued by National Medical Products Administration, and it was registered and classified as Class 1.2 innovative vaccine. The vaccine is an innovative vaccine independently developed by scientists in China with completely independent intellectual property rights, which is expected to play an important role in the prevention and control of diseases caused by monkeypox virus in China. (China Biology)
Strategy guide 12-13
Strategy guide
12-13
Strategy guide
12-13